Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Selfreported Risk Screening For Prep And Syndromic Management For Stis

Research Leaders

14 sponsors active, led by National Institute of Allergy and Infectious Diseases (NIAID)

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (3)
Phase 2 (1)

Trial Status

Completed4
Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (6)

Research Network

Common Treatments

  • Selfreported Risk Screening For Prep And Syndromic Management For Stis1
  • Aptima Trichomonas Vaginalis Atv Assay1
  • Patientdelivered Partner Treatment1
  • Solana Trichomonas Assay Testing1
  • Point Of Care Tests1

Active Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)3
  • Quidel Corporation1
  • Bill and Melinda Gates Foundation1
  • Louisiana State University Health Sciences Center in New Orleans1
  • Abbott1

Top Investigators

Related Conditions

  • Gonorrhea Female1
  • Hivaids1
  • Antenatal Care1
  • Birth Outcomes1
  • Chlamydia Trachomatis1

Activity Timeline